RTOG-1112

Terminated

Return to Protocol Table

Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma

Principal Investigator

Laura A. Dawson

Status

Terminated

Open to Accrual

April 24, 2013

Temporarily Closed to Accrual

June 27, 2019

Open to Accrual

July 12, 2019

Closed to Accrual

March 10, 2021

Closed to Accrual & Treatment

February 2, 2023

Terminated

September 4, 2025


Disease Site

Gastrointestinal [GI] Liver

Phase

III

Developmental Therapeutics

No

Primary Objective

To determine if SBRT improves overall survival in HCC patients treated with Sorafenib

Patient Population

Unsuitable for resection or transplant or radiofrequency ablation (RFA); Unsuitable for TACE or refractory to TACE; Barcelona Clinic Liver Cancer Stage (BCLC) Intermediate (B) or Advanced (C)

Target Accrual

368

Protocol Documents

Available via the National Cancer Institute (NCI) Cancer Trials Support Unit (CTSU) website.


Patient Study Webpage

There is no available patient study webpage available for this trial at this time.